RPS6KB1 and hepatocellular carcinoma: These observations indicated that BafA1 treatment (5 nM) inhibits the activation of the class I PI3K/Akt/mTOR/p70S6K signaling pathway in HCC cell lines, suggesting a cell or cancer-type specific effect by BafA1 at low concentration.